Eriodictyol inhibits high glucose‐induced oxidative stress and inflammation in retinal ganglial cells

Lv, Peilin; Yu, Jingni; Xu, Xiayu; Lu, Tianjian

doi:10.1002/jcb.27848

Cited by 60 publications

(47 citation statements)

References 22 publications

(90 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zhang et al () demonstrated that eriodictyol concentration dependently enhances insulin‐stimulated glucose uptake in both HepG2 cells and differentiated 3T3‐L1 adipocytes under HG conditions. An in vitro study demonstrated that eriodictyol might be a new therapeutic strategy for the management of diabetic retinopathy, which is one of the most common microvascular complications of diabetes mellitus and remains a leading cause of blindness (Lv et al, ). Eriodictyol improves cell viability of HG‐stimulated RGC‐5 cells.…”

Section: Discussionmentioning

confidence: 99%

“…Eriodictyol exerts protective effect on diabetic retinopathy, which is another most common microvascular complication of diabetes mellitus. Eriodictyol inhibits HG‐induced oxidative stress, inflammation, and cell apoptosis through regulating the activation of Nrf2/HO‐1 pathway in retinal ganglial cells (Lv, Yu, Xu, Lu, & Xu, ). In addition, eriodictyol prevents early retinal and plasma abnormalities in streptozotocin‐induced diabetic rats (Bucolo, Leggio, Drago, & Salomone, ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Eriodictyol inhibits high glucose‐induced extracellular matrix accumulation, oxidative stress, and inflammation in human glomerular mesangial cells

Bai

Wang

Zhu

et al. 2019

Phytotherapy Research

View full text Add to dashboard Cite

Diabetic nephropathy (DN) is one of the major complications of diabetes mellitus. The progression of DN has been found to be associated with high glucose (HG)-induced oxidative stress and inflammation in diabetes mellitus. Eriodictyol is a flavonoid that possesses antioxidant and anti-inflammatory effects. However, the effect of eriodictyol on DN remains unknown. In the present study, we evaluated the role of eriodictyol in mesangial cells (MCs) in response to HG condition. The results showed that eriodictyol repressed cell proliferation of HG-stimulated MCs. Treatment with eriodictyol attenuated oxidative stress, which was evidenced by increased superoxide dismutase activity as well as decreased production of reactive oxygen species (ROS) and malondialdehyde.Besides, eriodictyol suppressed the expressions of two NADPH oxidase (NOX) isoforms, NOX2 and NOX4, which are responsible for the generation of ROS. Eriodictyol suppressed the production of extracellular matrix proteins including fibronectin and Collagen IV, as well as the secretion of inflammatory cytokines including TNF-α, IL-1β, and IL-6 in HG-induced MCs. Moreover, the HG-induced activation of Akt/NF-κB pathway was mitigated by eriodictyol. In conclusion, eriodictyol protected MCs from HG stimulation though inhibition of Akt/NF-κB pathway.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Eriodictyol inhibits high glucose‐induced extracellular matrix accumulation, oxidative stress, and inflammation in human glomerular mesangial cells

Bai

Wang

Zhu

et al. 2019

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

“…Stimulation of the Nrf2/HO‐1 pathway is being studied for treatment of diseases that are caused by oxidative stress, including DR . Lv et al reported that eriodictyol protects the retinal ganglion cells from HG‐induced oxidative stress, inflammation, and cell apoptosis through regulating the activation of the Nrf2/HO‐1 pathway. In addition, blueberry anthocyanins have been found to protect retinal cells from diabetes‐induced oxidative stress and inflammation, which may be regulated by Nrf2/HO‐1 signalling .…”

Section: Discussionmentioning

confidence: 99%

“…22 Among these enzymes, HO-1 is a crucial enzyme that is involved in the oxidative stress. Stimulation of the Nrf2/HO-1 pathway is being studied for treatment of diseases that are caused by oxidative stress, including DR. 23,24 Lv et al 25 reported that eriodictyol protects the retinal ganglion cells from HG-induced oxidative stress, inflammation, and cell apoptosis through regulating the activation of the Nrf2/HO-1 pathway.…”

Section: Discussionmentioning

confidence: 99%

Knockdown of ALK7 inhibits high glucose‐induced oxidative stress and apoptosis in retinal pigment epithelial cells

Shi

Dong

Zhang

et al. 2019

Clin Exp Pharma Physio

View full text Add to dashboard Cite

Diabetic retinopathy (DR) is one of the diabetic complications associated with hyperglycaemia‐mediated oxidative stress. Activin receptor‐like kinase 7 (ALK7) has been proven to be a potential therapeutic approach for diabetic cardiomyopathy, which is another diabetic complication. However, the role of ALK7 in DR remains unclear. In the current study, ALK7 was found to be up‐regulated in clinical samples from DR patients and high glucose (HG)‐induced human retinal pigment epithelial cells (ARPE‐19). In vitro studies demonstrated that knockdown of ALK7 in ARPE‐19 cells through transfection with siRNA‐ALK7 (si‐ALK7) improved cell viability in HG‐induced ARPE‐19 cells. Knockdown of ALK7 suppressed HG‐induced reactive oxygen species (ROS) production, as well elevating the activities of superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH) in ARPE‐19 cells. The number of apoptotic cells was significantly decreased after transfection with si‐ALK7. ALK7 knockdown also caused a significant decrease in bax expression and an increase in bcl‐2 expression in HG‐induced ARPE‐19 cells. In addition, ALK7 knockdown resulted in remarkable increase in the expressions of nuclear factor (erythroid‐derived 2)‐like 2 (Nrf2) and heme oxygenase‐1 (HO‐1) in ARPE‐19 cells in response to HG induction. Taken together, knockdown of ALK7 protected ARPE‐19 cells from HG‐induced oxidative injury, which might be mediated by the activation of the Nrf2/HO‐1 signalling pathway.

show abstract

“…This anti-angiogenic effect was accompanied by an improvement in the oxidative and inflammatory state, evidenced by increased antioxidant enzymes (SOD and CAT) and reduced pro-oxidant enzymes (Nox4 and eNOS) and NF-κB activity [85]. Moreover, anti-inflammatory and anti-oxidant effects have also been demonstrated by myricetin, eriodyctiol and galangin in retinal epithelial, ganglial and microglial cells, respectively [84,86,87]. In addition, baicalin protects human retinal pigment epithelial cells against hyperglycemic conditions by reducing the proliferative, anti-apoptotic and anti-inflammatory effects by up-regulation of miR-145 and further inhibition of NF-κB and p38 MAPK pathways [88].…”

Section: Diabetic Retinopathymentioning

confidence: 99%

The Coming Age of Flavonoids in the Treatment of Diabetic Complications

Caro-Ordieres

Marín-Royo

Opazo-Ríos

et al. 2020

JCM

View full text Add to dashboard Cite

Diabetes mellitus (DM), and its micro and macrovascular complications, is one of the biggest challenges for world public health. Despite overall improvement in prevention, diagnosis and treatment, its incidence is expected to continue increasing over the next years. Nowadays, finding therapies to prevent or retard the progression of diabetic complications remains an unmet need due to the complexity of mechanisms involved, which include inflammation, oxidative stress and angiogenesis, among others. Flavonoids are natural antioxidant compounds that have been shown to possess anti-diabetic properties. Moreover, increasing scientific evidence has demonstrated their potential anti-inflammatory and anti-oxidant effects. Consequently, the use of these compounds as anti-diabetic drugs has generated growing interest, as is reflected in the numerous in vitro and in vivo studies related to this field. Therefore, the aim of this review is to assess the recent pre-clinical and clinical research about the potential effect of flavonoids in the amelioration of diabetic complications. In brief, we provide updated information concerning the discrepancy between the numerous experimental studies supporting the efficacy of flavonoids on diabetic complications and the lack of appropriate and well-designed clinical trials. Due to the well-described beneficial effects on different mechanisms involved in diabetic complications, the excellent tolerability and low cost, future randomized controlled studies with compounds that have adequate bioavailability should be evaluated as add-on therapy on well-established anti-diabetic drugs.

show abstract

Eriodictyol inhibits high glucose‐induced oxidative stress and inflammation in retinal ganglial cells

Cited by 60 publications

References 22 publications

Eriodictyol inhibits high glucose‐induced extracellular matrix accumulation, oxidative stress, and inflammation in human glomerular mesangial cells

Eriodictyol inhibits high glucose‐induced extracellular matrix accumulation, oxidative stress, and inflammation in human glomerular mesangial cells

Knockdown of ALK7 inhibits high glucose‐induced oxidative stress and apoptosis in retinal pigment epithelial cells

The Coming Age of Flavonoids in the Treatment of Diabetic Complications

Contact Info

Product

Resources

About